Pharmaceutical manufacturers are increasingly turning to reusable plastic pallets as pressure mounts to deliver high-value products safely, sustainably, and efficiently.
ORBIS Corporation strategic account manager Matt Marchetti says the shift reflects growing industry focus on security, traceability, sustainability, and automation efficiency across pharmaceutical supply chains.
Reusable plastic pallets offer superior durability, enhanced hygiene, and long-term reusability compared with traditional single-use alternatives, making them well suited to pharmaceutical environments.
However, Marchetti notes that transitioning from single-use to reusable packaging requires a strategic shift in how organisations evaluate packaging performance, cost, and sustainability outcomes.
Understanding and defining the supply chain impact is a crucial step, requiring a multi-faceted approach that involves determining key performance indicators and implementing solutions based on real-time data insights.
One of the primary concerns in pharmaceutical logistics is product protection, as pallets regularly carry high-value goods that must arrive fully intact and undamaged throughout the supply chain.
Marchetti points out that smooth surfaces and contoured edges on plastic pallets prevent damage to cartons and ensure product quality and security, eliminating risks associated with nails or loose boards on wood pallets.
Traceability is another critical consideration, giving companies full visibility throughout the supply chain in situations involving a product recall or loss.
As manufacturing operations become increasingly automated, companies also require pallet solutions designed to integrate seamlessly with those automated systems, adding another layer of operational value.
When evaluating a transition, companies pay close attention to key performance indicators and current good manufacturing practices relevant to their unique supply chain goals.
Potential metrics include less system downtime, impact on the environment, reduced product damage, reliability, quality compliance, and enhanced security across the operation.
Life-cycle assessment metrics enable the quantification of solid waste, energy use, and greenhouse gas emissions differences between reusable and single-use packaging options, strengthening the environmental case.
Pilot programmes using limited pallet subsets can generate operational evidence, helping organisations build internal return on investment cases before committing to wider rollout.
Marchetti argues that successful closed-loop execution requires provider-supported asset management, covering cleaning, tracking, repair, and replenishment, with financing flexibility to reduce adoption barriers.
Pharmaceutical companies that approach the transition with clarity and commitment recognise that the shift benefits people, the planet, and the business as a whole, according to Marchetti.
He emphasises the importance of viewing reusable packaging as a valuable company asset rather than simply “one more thing to track,” transforming it into a strategic tool that drives long-term business improvement.